Detail akcie Cellectis online

Business Summary: Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Cellectis SA revenues decreased 64% to $9.2M. Net loss applicable to common stockholders excluding extraordinary items increased 21% to $109.5M. Revenues reflect France segment decrease of 96% to $755K. Higher net loss reflects Foreign exchange loss increase from $1.5M to $13.4M (expense), Other operating income (expenses) increase from $1.4M (income) to $1.3M (expense).